一项新发现与ATF3/DOCK8在阿尔茨海默氏症病原发生过程中的参与有关
Wenqiang Zhang1,2, Fei Teng3, Xifa Lan1
1Department of Neurology, The First Hospital of Qinhuangdao, Qinhuangdao, Hebei, People's Republic of China.
Journal of Alzheimer's disease : JAD
|April 23, 2025
概括
在阿尔茨海默氏症 (AD) 中,细胞动力学8 (DOCK8) 分割体的高表达通过增强微质细胞迁移加速了粉样蛋白β斑块的产生. 在小鼠模型中,减少DOCK8表达改善了认知功能,并减少了斑块沉积.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 神经退行性疾病的发病因子
背景情况:
- 微质细胞在阿尔茨海默氏症 (AD) 病原发生过程中发挥着关键作用,通过影响粉样蛋白β (Aβ) 斑块沉积.
- 在神经退行性疾病的小鼠模型中,细胞动力学8 (DOCK8) 分辨器的删除显示出保护作用.
研究的目的:
- 调查DOCK8在阿尔茨海默病发展中的具体作用和潜在机制.
主要方法:
- 检查了APP/PS1小鼠海马中的DOCK8表达.
- 在APP/PS1小鼠中进行DOCK8敲除,以评估对认知,微质迁移和Cdc42/p38 MAPK通路的影响.
- 研究了DOCK8对Aβ诱导的BV-2细胞迁移和激活的影响.
- 使用双 luciferase 记者测定来确定 ATF3 的 DOCK8.8 的转录调节.
主要成果:
- 在APP/PS1小鼠的海马中,DOCK8的表达显著上调.
- DOCK8的淘汰导致了认知恢复,减少了微质表达,并减少了向Aβ斑块的迁移.
- 通过ATF3介导的高DOCK8表达激活了Cdc42/p38 MAPK通路,促进了微质的迁移和Aβ斑块的形成.
结论:
- 在阿尔茨海默病中,通过ATF3调节的DOCK8加速了Aβ斑块的产生.
- DOCK8是阿尔茨海默病的发病的一个关键参与者,影响微质活动和斑块沉积.
相关概念视频
Alzheimer's Disease: Overview
317
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
317
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128


